PMID- 7683357
OWN - NLM
STAT- MEDLINE
DCOM- 19930601
LR  - 20181130
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 7 Suppl 1
DP  - 1993 May
TI  - Preliminary results with 5-aza-2'-deoxycytidine (DAC)-containing chemotherapy in 
      patients with relapsed or refractory acute leukemia. The EORTC Leukemia 
      Cooperative Group.
PG  - 49-50
AB  - Twenty two patients with acute relapsed leukemia (AML 20, ALL 2) were treated 
      with 5-aza-2'-deoxycytidine (DAC) and either m-amsacrine or idarubicin. DAC was 
      administered as a 6-h infusion, every 12 h for 6 days in combination with either 
      m-amsacrine (120 mg/m2) as a 1-h infusion on days 6 and 7 (n = 19) or idarubicin 
      (12 mg/m2) as a 15-min infusion on days 5, 6 and 7 (n = 3). Thirteen patients 
      (59%) achieved a complete remission. The treatment was complicated by nausea, 
      vomiting, diarrhoea with signs of peritonitis (n = 9), weight loss (n = 7), 
      cerebellar or cerebral toxicity (n = 2), gastrointestinal bleeding (n = 3), liver 
      toxicity (n = 2) and prolonged myelosuppression. Median duration of remission was 
      4 months (range 1-30). The preliminary data show that DAC is an anti-leukemic 
      agent, comparable to high dose Ara-C with comparable severe toxicity.
FAU - Willemze, R
AU  - Willemze R
AD  - Department of Hematology, Leiden University Medical Center, The Netherlands.
FAU - Archimbaud, E
AU  - Archimbaud E
FAU - Muus, P
AU  - Muus P
LA  - eng
PT  - Journal Article
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Antineoplastic Agents)
RN  - 00DPD30SOY (Amsacrine)
RN  - 776B62CQ27 (Decitabine)
RN  - M801H13NRU (Azacitidine)
RN  - ZRP63D75JW (Idarubicin)
SB  - IM
MH  - Acute Disease
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Amsacrine/administration & dosage
MH  - Antineoplastic Agents/*therapeutic use
MH  - Azacitidine/*analogs & derivatives/therapeutic use
MH  - Decitabine
MH  - Female
MH  - Humans
MH  - Idarubicin/administration & dosage
MH  - Leukemia, Myeloid/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/*drug therapy
MH  - Recurrence
MH  - Remission Induction
EDAT- 1993/05/01 00:00
MHDA- 1993/05/01 00:01
CRDT- 1993/05/01 00:00
PHST- 1993/05/01 00:00 [pubmed]
PHST- 1993/05/01 00:01 [medline]
PHST- 1993/05/01 00:00 [entrez]
PST - ppublish
SO  - Leukemia. 1993 May;7 Suppl 1:49-50.